Connect with us

BioPharma

Dmg Blockchain Solutions Inc (OTCMKTS: DMGGF) Steady Run Northbound as Crypto Operator Makes Waves in a Fast-Growing Space

Published

on

Dmg Blockchain Solutions Inc (OTCMKTS: DMGGF) is making a powerful move northbound as the price of BTC breaks out of its trading range and looks to make new highs. Dmg Blockchain is getting plenty of attention from investors for its intuitive moves to monetize the blockchain ecosystem. The Company operates its data center in Christina Lake, BC. The Data Centre is 100% owned by DMG and includes its own privately constructed 85-megawatt substation on DMG’s thirty-three acre property along with a 27,000 square foot building. Due to the success of Christina Lake’s operations, DMG is now seriously investigating additional sites. DMG has entered into discussions with multiple parties where it believes its expertise and its supply chain capabilities can move quickly to low cost, high margin future sites. The Company is hoping to conclude negotiations in the near future and announce additional DMG sites. 

Sales are rising quickly; Revenue for the three months ended June 30, 2021 was $1,702,275 a increase of $339,042 as compared to the three months ended June 30, 2020. Mining equipment hosting increased by $543,198 compared to the three months ended June 30, 2020. The increase is attributable to an increase in hosting clients as compared to the prior period. The increase in revenue was offset by a decrease in digital currency mining of $66,466 and a decrease of $137,790 in consulting and forensics income. The Company is well funded moving forward with $47.4 million in the treasury. 

Dmg Blockchain Solutions Inc (OTCMKTS: DMGGF) is an environmentally friendly vertically integrated blockchain and cryptocurrency company that manages, operates, and develops end-to-end digital solutions to monetize the blockchain ecosystem. DMG’s sustainable businesses are segmented into two business lines under the Core and Core+ strategies and unified through DMG’s vertical integration. 

DMG operates its data center in Christina Lake, BC. The Data Centre is 100% owned by DMG and includes its own privately constructed 85-megawatt substation on DMG’s thirty-three acre property along with a 27,000 square foot building. Owning this asset gives the company many advantages in power infrastructure, which is the primary need of any crypto mining operation. By owning its infrastructure, DMG is not only free from leases and landlords, but also is independent from drawing community needs for power where it operates. Due to the location selected DMG is also investigating the addition of both solar power generation and a small investment in hydrogen production as both a long-term revenue generation stream and as part of the company’s renewables strategy. 

Due to the success of Christina Lake’s operations, DMG is now seriously investigating additional sites. DMG has entered into discussions with multiple parties where it believes its expertise and its supply chain capabilities can move quickly to low cost, high margin future sites. The Company is hoping to conclude negotiations in the near future and announce additional DMG sites. 

In early 2018, DMG acquired Datient Inc., a Silicon Valley-based technology company with a mixture of great data scientists that had created the Blockseer brand name with its first product which was an analytics tool that enables tracking of initially Bitcoin and then transactions on both the Bitcoin and Ethereum blockchains. However, over the years DMG has found more ways to develop this technology. After the acquisition of Datient, DMG invested in developing Walletscore due to the value of Blockseer’s data. Now we are continuing the development of this platform focused on two distinct crypto categories: Safety & Security and Regulatory & Compliance. 

To Find out the inside Scoop on DMG Blockchain Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

DMGGF

The Company currently has the launches of Blockseer Breeze and Blockseer Freeze planned for Q4, 2021; Blockseer Breeze: Planned for Q4 2021, this platform is focused on equipping anyone from individual crypto wallet users to financial institutions with an enterprise-grade custody solution to securely manage digital assets with the choice of single or multiple signatures to execute a crypto transaction. Blockseer Freeze: Planned for Q4 2021, this software product monitors Bitcoin wallets, notifying the owner(s) of any transactions and provides a mechanism to stop suspicious transactions from being executed. 

On October 20 DMG Blockchain announced multiple successful transactions with Zodia Custody (www.zodia.io), a crypto asset custodian incubated by Standard Chartered (www.sc.com), with Northern Trust (www.northerntrust.com) as a co-investor, using DMG’s Blockseer platform “Petra” from its Core+ suite of services. 

On Monday, Oct 11, 2021, using a testnet environment, DMG initiated a new function called Petra, which gives subscribers enhanced optionality when initiating crypto transactions. The test transactions were carried out alongside Zodia Custody. The addition of optionality — once fully completed and launched under the Blockseer brand — will provide subscribers a choice in how they want to proceed with transactions. The options provided by Petra will include the provision of KYC on wallets, AML checks on transactions, and routing transactions via carbon neutral mining facilities. This is an important step in the development of DMG’s Regulatory & Compliance offerings under Blockseer’s platforms. 

Once completed, Petra’s launch will provide options focused on the Bitcoin Blockchain. As part of the tests conducted alongside Zodia Custody, transactions were routed using Petra and tagged as a “green” to prioritise carbon neutral miners, giving one example of the optionality provided by the platform. Future options may include risk ratings of counterparties and geo-location. Petra’s subscriptions will be based on a percentage of the dollar-value equivalent that is transacted through the system. 

DMG’s CEO Sheldon Bennett, comments, “Petra is a concept that DMG conceived many years ago. However, we did not have the technology to bring this concept to the market until now. Using core technologies in Blockseer’s Walletscore, Explorer and Helm, we have been able to create a new and very relevant product for companies and individuals who have particular interest in governance, regulatory issues, and ESG goals aligned with optionality that Petra permits. Our partnership with Zodia Custody is moving quickly and we look forward to completing all our testing and bringing this product to market.” 

“The crypto asset industry is often associated with high environmental impacts, particularly in relation to energy consumption. Further, the concept of unknown participants mining blocks is outside of many institutions’ risk appetite. Zodia Custody, in an industry first with DMG’s Petra platform, is able to address these concerns and offer our clients the option to route transfers to OFAC-compliant, ‘green’ mining pools. Petra will also give comfort to our institutional clients that their crypto transfers are being processed by known, sanctioned complaint parties. This represents a major milestone towards the institutional adoption of crypto assets and demonstrates Zodia’s commitment to providing safe access to this market for highly-regulated global financial institutions in a way that is aligned with their goals,” said, Maxime De Guillebon, CEO, Zodia Custody. 

 For More on AHFD Subscribe Right Now!

Dmg Blockchain Solutions Inc is making a powerful move northbound as the price of BTC breaks out of its trading range and looks to make new highs. Dmg Blockchain is getting plenty of attention from investors for its intuitive moves to monetize the blockchain ecosystem. The Company operates its data center in Christina Lake, BC. The Data Centre is 100% owned by DMG and includes its own privately constructed 85-megawatt substation on DMG’s thirty-three acre property along with a 27,000 square foot building. Due to the success of Christina Lake’s operations, DMG is now seriously investigating additional sites. DMG has entered into discussions with multiple parties where it believes its expertise and its supply chain capabilities can move quickly to low cost, high margin future sites. The Company is hoping to conclude negotiations in the near future and announce additional DMG sites. Sales are rising quickly; Revenue for the three months ended June 30, 2021 was $1,702,275 a increase of $339,042 as compared to the three months ended June 30, 2020. Mining equipment hosting increased by $543,198 compared to the three months ended June 30, 2020. The increase is attributable to an increase in hosting clients as compared to the prior period. The increase in revenue was offset by a decrease in digital currency mining of $66,466 and a decrease of $137,790 in consulting and forensics income. The Company is well funded moving forward with $47.4 million in the treasury. We will be updating on DMG Blockchain when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with DMG Blockchain.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in DMG Blockchain either long or short and we have not been compensated for this article.

 

Dmg Blockchain Solutions Inc (OTCMKTS: DMGGF)

 

Dmg Blockchain Solutions Inc (OTCMKTS: DMGGF) is an environmentally friendly vertically integrated blockchain and cryptocurrency company that manages, operates, and develops end-to-end digital solutions to monetize the blockchain ecosystem. DMG’s sustainable businesses are segmented into two business lines under the Core and Core+ strategies and unified through DMG’s vertical integration.
DMG operates its data centre in Christina Lake, BC. The Data Centre is 100% owned by DMG and includes its own privately constructed 85-megawatt substation on DMG’s thirty-three acre property along with a 27,000 square foot building. Owning this asset gives the company many advantages in power infrastructure, which is the primary need of any crypto mining operation. By owning its infrastructure, DMG is not only free from leases and landlords, but also is independent from drawing community needs for power where it operates. Due to the location selected DMG is also investigating the addition of both solar power generation and a small investment in hydrogen production as both a long-term revenue generation stream and as part of the company’s renewables strategy.
Due to the success of Christina Lake’s operations, DMG is now seriously investigating additional sites. DMG has entered into discussions with multiple parties where it believes its expertise and its supply chain capabilities can move quickly to low cost, high margin future sites. The Company is hoping to conclude negotiations in the near future and announce additional DMG sites.
DMG’s core infrastructure operations are the foundation of its vertical integration strategy. Our core operations focus on earning revenues from block rewards and transaction fees by mining primarily bitcoin as well as providing hosting services and supplying crypto-mining hardware for industrial mining clients.
DMG’s data analytics and forensic services provide technical expertise software products such as Blockseer Pool, Mine Manager, and Walletscore, as well as working with auditors, law firms, and law enforcement organizations.
DMG’s mission is to become the domain expert across the business vertical of blockchain mining and become a business operation with a myriad of options for innovation, economies of scale, risk mitigation, sustainability, and investment protection.

On October 20 DMG Blockchain announced multiple successful transactions with Zodia Custody (www.zodia.io), a crypto asset custodian incubated by Standard Chartered (www.sc.com), with Northern Trust (www.northerntrust.com) as a co-investor, using DMG’s Blockseer platform “Petra” from its Core+ suite of services.
On Monday, Oct 11, 2021, using a testnet environment, DMG initiated a new function called Petra, which gives subscribers enhanced optionality when initiating crypto transactions. The test transactions were carried out alongside Zodia Custody. The addition of optionality — once fully completed and launched under the Blockseer brand — will provide subscribers a choice in how they want to proceed with transactions. The options provided by Petra will include the provision of KYC on wallets, AML checks on transactions, and routing transactions via carbon neutral mining facilities. This is an important step in the development of DMG’s Regulatory & Compliance offerings under Blockseer’s platforms.
Once completed, Petra’s launch will provide options focused on the Bitcoin Blockchain. As part of the tests conducted alongside Zodia Custody, transactions were routed using Petra and tagged as a “green” to prioritise carbon neutral miners, giving one example of the optionality provided by the platform. Future options may include risk ratings of counterparties and geo-location. Petra’s subscriptions will be based on a percentage of the dollar-value equivalent that is transacted through the system.
DMG’s CEO Sheldon Bennett, comments, “Petra is a concept that DMG conceived many years ago. However, we did not have the technology to bring this concept to the market until now. Using core technologies in Blockseer’s Walletscore, Explorer and Helm, we have been able to create a new and very relevant product for companies and individuals who have particular interest in governance, regulatory issues, and ESG goals aligned with optionality that Petra permits. Our partnership with Zodia Custody is moving quickly and we look forward to completing all our testing and bringing this product to market.”
“The crypto asset industry is often associated with high environmental impacts, particularly in relation to energy consumption. Further, the concept of unknown participants mining blocks is outside of many institutions’ risk appetite. Zodia Custody, in an industry first with DMG’s Petra platform, is able to address these concerns and offer our clients the option to route transfers to OFAC-compliant, ‘green’ mining pools. Petra will also give comfort to our institutional clients that their crypto transfers are being processed by known, sanctioned complaint parties. This represents a major milestone towards the institutional adoption of crypto assets and demonstrates Zodia’s commitment to providing safe access to this market for highly-regulated global financial institutions in a way that is aligned with their goals,” said, Maxime De Guillebon, CEO, Zodia Custody.

About Zodia Custody
Zodia Custody, an institutional grade crypto asset custody solution based in London, offers services to clients across the globe. Zodia Custody enables institutions to invest safely and securely in crypto assets. Developed by Standard Chartered Ventures and Northern Trust, Zodia Custody satisfies institutional investors’ need for a crypto asset custodian that understands traditional custody and meets investors’ standards and expectations, whilst maintaining the flexibility required to adapt to the ever-changing crypto asset market.

Zodia Custody is registered with the FCA under the Money Laundering, Terrorist Financing and Transfer of Funds Regulations 2017 and has commenced commercial operations following a period of testing.

Zodia Custody is providing custody services for the two most traded crypto assets, Bitcoin and Ethereum, with plans to expand to more crypto assets based on thorough risk assessment and client demand.

Zodia Custody Limited is registered with the UK Financial Conduct Authority with Firm Reference Number 928347.

For more information visit our website or follow us on LinkedIn.

 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

on

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

on

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.